Cemiplimab vs Pembrolizumab berahyaluronidase alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabPembrolizumab berahyaluronidase alfa
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
—Trial running · NCT05722015
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
—Trial running · NCT05722015
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
—Trial running · NCT05722015

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemiplimab: 4 of 4 rows · Pembrolizumab berahyaluronidase alfa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabPembrolizumab berahyaluronidase alfa
Dropout rate
79%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneb
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
0.3%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—b
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
36.8%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
39%b
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
b
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

Overall Survival 23.4 vs 13.7 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
15.9 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
20.1 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
21.1 vs 12.9 placebo months
NCT03409614 · Phase 3 · combination
PFS 6.3 vs 5.3 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
6.5 vs 6.4 Chemotherapy months
NCT03409614 · Phase 3 · combination
6.4 vs 6.4 Chemotherapy months
NCT03409614 · Phase 3 · combination
8.2 vs 5.5 placebo months
NCT03409614 · Phase 3 · combination
Duration of Response 24.1 vs 5.9 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
7.8 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
15.9 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
16.4 vs 7.3 placebo months
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.1 vs -3.03 Chemotherapy score @ 51wk
absolute change · score
C18D1
NCT03088540 · Phase 3
show 3 more results
6.73 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
14.44 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
5.28 vs 10.09 placebo score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination

+ 39 further endpoints in the CSV export.

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Phase 3 in Melanomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT05608291 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Melanomamonoclonal antibody
Partial signal

NCT06099782 · Phase 2 · active, not recruiting

Patients were randomized to the order in which they received the two routes, but the study was open-label, and its primary endpoint was the share of patients who preferred the subcutaneous route, a single percentage with no formal comparison. It measured preference and convenience, not whether the drug controls cancer, so it is limited evidence.

No aligned efficacy figure on record for this race.

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: registry results are on file for Melanoma, but their comparison mappings are not yet available.

Available safety results

Cemiplimab

Dropout rate
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
Serious AEs
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Pembrolizumab berahyaluronidase alfa's landscape